neurogenetics

, Volume 14, Issue 2, pp 123–132 | Cite as

Dominant GDAP1 founder mutation is a common cause of axonal Charcot-Marie-Tooth disease in Finland

  • Mari Auranen
  • Emil Ylikallio
  • Jussi Toppila
  • Mirja Somer
  • Sari Kiuru-Enari
  • Henna Tyynismaa
Original Article

Abstract

We describe a founder mutation in the gene encoding ganglioside-induced differentiation associated-protein 1 (GDAP1), leading to amino acid change p.H123R, as a common cause of autosomal dominant axonal Charcot-Marie-Tooth (CMT2) neuropathy in Finland. The mutation explains up to 14 % of CMT2 in Finland, where most patients with axonal neuropathy have remained without molecular diagnosis. Only three families out of 28 were found to carry putative disease mutations in the MFN2 gene encoding mitofusin 2. In addition, the MFN2 variant p.V705I was commonly found in our patients, but we provide evidence that this previously described mutation is a common polymorphism and not pathogenic. GDAP1-associated polyneuropathy caused predominantly a mild and slowly progressive phenotype. Besides distal leg muscle weakness, most patients showed mild proximal weakness, often with asymmetry and pes cavus. Our findings broaden the understanding of GDAP1 mutations in CMT2 phenotypes and provide support for the use of whole-exome sequencing in CMT gene diagnostics.

Keywords

Charcot-Marie-Tooth disease Axonal neuropathy GDAP1 Founder mutation Exome sequencing 

Supplementary material

10048_2013_358_Fig5_ESM.jpg (62 kb)
ESM 1

Filtering steps of the exome data using the unbiased approach. From each of the families 1 and 2, two related CMT2 patients were subjected to exome sequencing. The number of variants for each filtering step are shown. The selected variants were the following: (1) Intragenic, (2) Heterozygous on autosomes, (3) Rare in the 1000Genomes project (<0.5 % frequency), (4) Nonsynonomous, (5) Predicted damaging by the SIFT Tool, (6) Shared by the two affected family members, (7) Not present in our in-house database of exome data from Finnish individuals (n = 50). (JPEG 61 kb)

10048_2013_358_MOESM1_ESM.tif (3.2 mb)
High-resolution image (TIFF 3,261 kb)
10048_2013_358_MOESM2_ESM.pdf (7 kb)
ESM 2(PDF 6 kb)

References

  1. 1.
    Patzko A, Shy ME (2011) Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep 11(1):78–88PubMedCrossRefGoogle Scholar
  2. 2.
    Szigeti K, Lupski JR (2009) Charcot-Marie-Tooth disease. Eur J Hum Genet 17(6):703–710PubMedCrossRefGoogle Scholar
  3. 3.
    Braathen GJ, Sand JC, Lobato A, Hoyer H, Russell MB (2011) Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 18(1):39–48PubMedCrossRefGoogle Scholar
  4. 4.
    Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME (2011) Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69(1):22–33PubMedCrossRefGoogle Scholar
  5. 5.
    Zuchner S, Mersiyanova IV, Muglia M et al (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36(5):449–451PubMedCrossRefGoogle Scholar
  6. 6.
    Lupski JR, Reid JG, Gonzaga-Jauregui C et al (2010) Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 362(13):1181–1191PubMedCrossRefGoogle Scholar
  7. 7.
    Choi BO, Koo SK, Park MH, Rhee H, Yang SJ, Choi KG, Jung SC, Kim HS, Hyun YS, Nakhro K, Lee HJ, Woo HM, Chung KW (2012) Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth Disease. Hum Mutat (in press)Google Scholar
  8. 8.
    Silander K, Meretoja P, Juvonen V, Ignatius J, Pihko H, Saarinen A, Wallden T, Herrgard E, Aula P, Savontaus ML (1998) Spectrum of mutations in Finnish patients with Charcot-Marie-Tooth disease and related neuropathies. Hum Mutat 12(1):59–68PubMedCrossRefGoogle Scholar
  9. 9.
    Sulonen AM, Ellonen P, Almusa H, Lepisto M, Eldfors S, Hannula S, Miettinen T, Tyynismaa H, Salo P, Heckman C, Joensuu H, Raivio T, Suomalainen A, Saarela J (2011) Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol 12(9):R94PubMedCrossRefGoogle Scholar
  10. 10.
    Zuchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas F, Bird T, Timmerman V, Shy M, Vance JM (2006) Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59(2):276–281PubMedCrossRefGoogle Scholar
  11. 11.
    Braathen GJ, Sand JC, Lobato A, Hoyer H, Russell MB (2010) MFN2 point mutations occur in 3.4 % of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 11:48PubMedCrossRefGoogle Scholar
  12. 12.
    Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen JT, Meins M (2006) Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet 7:53PubMedCrossRefGoogle Scholar
  13. 13.
    Zimon M, Baets J, Fabrizi GM, Jaakkola E, Kabzinska D, Pilch J, Schindler AB, Cornblath DR, Fischbeck KH, Auer-Grumbach M, Guelly C, Huber N, De Vriendt E, Timmerman V, Suter U, Hausmanowa-Petrusewicz I, Niemann A, Kochanski A, De Jonghe P, Jordanova A (2011) Dominant GDAP1 mutations cause predominantly mild CMT phenotypes. Neurology 77(6):540–548PubMedCrossRefGoogle Scholar
  14. 14.
    Crimella C, Tonelli A, Airoldi G, Baschirotto C, D’Angelo MG, Bonato S, Losito L, Trabacca A, Bresolin N, Bassi MT (2010) The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2 K. J Med Genet 47(10):712–716PubMedCrossRefGoogle Scholar
  15. 15.
    Baxter RV, Ben Othmane K, Rochelle JM, Stajich JE, Hulette C, Dew-Knight S, Hentati F, Ben Hamida M, Bel S, Stenger JE, Gilbert JR, Pericak-Vance MA, Vance JM (2002) Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 30(1):21–22PubMedCrossRefGoogle Scholar
  16. 16.
    Cuesta A, Pedrola L, Sevilla T, Garcia-Planells J, Chumillas MJ, Mayordomo F, LeGuern E, Marin I, Vilchez JJ, Palau F (2002) The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 30(1):22–25PubMedCrossRefGoogle Scholar
  17. 17.
    Claramunt R, Pedrola L, Sevilla T, Lopez de Munain A, Berciano J, Cuesta A, Sanchez-Navarro B, Millan JM, Saifi GM, Lupski JR, Vilchez JJ, Espinos C, Palau F (2005) Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J Med Genet 42(4):358–365PubMedCrossRefGoogle Scholar
  18. 18.
    Chung KW, Kim SM, Sunwoo IN, Cho SY, Hwang SJ, Kim J, Kang SH, Park KD, Choi KG, Choi IS, Choi BO (2008) A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet 53(4):360–364PubMedCrossRefGoogle Scholar
  19. 19.
    Cassereau J, Chevrollier A, Gueguen N, Malinge MC, Letournel F, Nicolas G, Richard L, Ferre M, Verny C, Dubas F, Procaccio V, Amati-Bonneau P, Bonneau D, Reynier P (2009) Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K). Neurogenetics 10(2):145–150PubMedCrossRefGoogle Scholar
  20. 20.
    Sivera R, Espinos C, Vilchez JJ, Mas F, Martinez-Rubio D, Chumillas MJ, Mayordomo F, Muelas N, Bataller L, Palau F, Sevilla T (2010) Phenotypical features of the p.R120W mutation in the GDAP1 gene causing autosomal dominant Charcot-Marie-Tooth disease. J Peripher Nerv Syst 15(4):334–344PubMedCrossRefGoogle Scholar
  21. 21.
    Sevilla T, Jaijo T, Nauffal D, Collado D, Chumillas MJ, Vilchez JJ, Muelas N, Bataller L, Domenech R, Espinos C, Palau F (2008) Vocal cord paresis and diaphragmatic dysfunction are severe and frequent symptoms of GDAP1-associated neuropathy. Brain 131(Pt 11):3051–3061PubMedCrossRefGoogle Scholar
  22. 22.
    Detmer SA, Chan DC (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8(11):870–879PubMedCrossRefGoogle Scholar
  23. 23.
    Chen H, McCaffery JM, Chan DC (2007) Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130(3):548–562PubMedCrossRefGoogle Scholar
  24. 24.
    Niemann A, Ruegg M, La Padula V, Schenone A, Suter U (2005) Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 170(7):1067–1078PubMedCrossRefGoogle Scholar
  25. 25.
    Marco A, Cuesta A, Pedrola L, Palau F, Marin I (2004) Evolutionary and structural analyses of GDAP1, involved in Charcot-Marie-Tooth disease, characterize a novel class of glutathione transferase-related genes. Mol Biol Evol 21(1):176–187PubMedCrossRefGoogle Scholar
  26. 26.
    Niemann A, Wagner KM, Ruegg M, Suter U (2009) GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol Dis 36(3):509–520PubMedCrossRefGoogle Scholar
  27. 27.
    Estela A, Pla-Martin D, Sanchez-Piris M, Sesaki H, Palau F (2011) Charcot-Marie-Tooth-related gene GDAP1 complements cell cycle delay at G2/M phase in Saccharomyces cerevisiae fis1 gene-defective cells. J Biol Chem 286(42):36777–36786PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Mari Auranen
    • 1
    • 2
  • Emil Ylikallio
    • 1
  • Jussi Toppila
    • 3
  • Mirja Somer
    • 4
  • Sari Kiuru-Enari
    • 2
  • Henna Tyynismaa
    • 1
    • 5
  1. 1.Research Programs Unit, Molecular Neurology, Biomedicum-HelsinkiUniversity of HelsinkiHelsinkiFinland
  2. 2.Department of NeurologyHelsinki University Central HospitalHelsinkiFinland
  3. 3.HUS Medical Imaging Center, Department of Clinical NeurophysiologyHelsinki University Central HospitalHelsinkiFinland
  4. 4.Department of Medical GeneticsVaestoliitto, The Family Federation of FinlandHelsinkiFinland
  5. 5.Department of Medical Genetics, Haartman InstituteUniversity of HelsinkiHelsinkiFinland

Personalised recommendations